390 results about "Polycyclic compound" patented technology

Compounds of formula (I) useful as cancer treatment, the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of certain diseases or disorders are disclosed.

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #

The invention relates to a pyrimidine-containing polybasic ring derivative inhibitor as well as a preparation method and application thereof. In particular, the invention relates to a pyrimidine-containing multi-element fused ring compound or a stereoisomer thereof, a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound or the stereoisomer thereof in preparation of drugs for treating cancers and other related diseases.

The invention belongs to the technical field of OLEDs, and provides a polycyclic compound containing triphenyl silicon and a polyalkyl substituent group and an organic electroluminescent device containing the polycyclic compound. The structural general formula of the polycyclic compound is as shown in formula I in the specification. Benzofuran with higher electronegativity is introduced to a ring structure composed of nitrogen atoms and boron atoms, triphenyl silicon is introduced to the para-position of boron, and the synergistic effect of benzofuran and triphenyl silicon can significantly enhance the multiple resonance of a light-emitting core and reduce vibration relaxation. Due to simultaneous use of the benzofuran and the triphenyl silicon, the problems of vibration relaxation increase, spectrum widening and the like caused by introduction of the polyalkyl substituent are remarkably improved, the luminous efficiency of the material is remarkably improved, and the color purity is improved, so that the requirement of BT.2020 wide color gamut display standard on a luminescent spectrum is met. I

The invention belongs to the technical field of organic light-emitting materials, and relates to a boron-containing polycyclic compound for an organic light-emitting material. According to the invention, aryl or heteroaryl is taken as a center, 2-3 boron atoms are introduced and form covalent bonds with atoms such as N, O, S and Se, and a rigid polycyclic compound is constructed. The compound provided by the invention is a boron-containing polycyclic compound with multiple resonance effects, can realize narrow-spectrum and high-color-purity luminescence, also has efficient TADF characteristics, and significantly improves the performance of OLED devices. Compared with the prior art, the compound has remarkable advantages in the aspects of molecular structure design, photoelectric property regulation and control, application range and the like, provides important technical support for development of new-generation high-performance OLED materials, and has wide market prospects and application potential.

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-E) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #

The present disclosure relates to a polycyclic compound, a preparation method therefor, and the pharmaceutical use thereof. Specifically, the present disclosure relates to a polycyclic compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a therapeutic agent, in particular, the use as an RAS inhibitor and the use in the preparation of a drug for treating and / or preventing RAS-mediated or dependent diseases or conditions, wherein each group in general formula (I) is as defined in the description.

A light emitting device according to an embodiment includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region. The emission layer includes a fused polycyclic compound represented by Formula 1, which is defined in the specification.

The present invention relates to an organic light-emitting device employing, as a host of a light emission layer, an anthracene derivative compound having a characteristic structure by introduction of a benzofuran structure into the anthracene backbone, and as a dopant of the light emission layer, a polycyclic compound having a characteristic structure. The organic light-emitting device according to the present invention is an organic light-emitting device with significantly improved external quantum efficiency and can be advantageously utilized not only for lighting devices but also for various display devices, such as flat, flexible, and wearable displays.

The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. As a GLP-1R agonist, the compound and the pharmaceutical composition thereof can be used for preparing drugs for treating and / or preventing diseases mediated by GLP-1R. # imgabs0 #

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-C) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #

The present invention relates to a polycyclic compound having a characteristic fused ring structure represented by the following [Formula 1], and a high-efficiency and long-lifetime organic electroluminescent device having excellent luminous efficiency and significantly improved lifetime and the like by employing the same in a light emitting layer in the organic electroluminescent device.

An organic electroluminescence device includes: a first electrode; a second electrode disposed on the first electrode; and at least one organic layer disposed between the first electrode and the second electrode. wherein the at least one organic layer includes a polycyclic compound having a core structure including a n,n′-bicarbazole moiety and, outside the core structure, at least one optionally substituted carbazole group, and the substituted or unsubstituted carbazole groups of the core structure substituted at any one among carbon atoms at position n±1 of the n,n′-bicarbazole moiety, and any one among carbon atoms at position n′±1 of the n,n′-bicarbazole moiety, respectively; and n and n′ are, independently from one another, integers of 1 to 4 (where n±1 and n′±1 are not 0).

A substituted polycyclic compound having biological inhibitory activity represented by formula (II), a preparation method therefor, and a use thereof. The use comprises a use of the compound of formula (II) in the preparation of a drug for treating MLL-related diseases. In the preparation process, the compound is obtained by means of a series of reactions such as substitution, cyclization, reduction, and deprotection.

The invention relates to a method for semi-solid-phase synthesis of a polycyclic compound and an intermediate, a long chain is synthesized through solid phase, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, starting materials for solid-phase synthesis are selected, steric hindrance is effectively avoided, and solid-phase reaction and subsequent liquid-phase correlation cyclization can be smoothly carried out, so that the yield is improved, and the cost is reduced.

A light-emitting element including a first electrode, a second electrode provided on the first electrode, and an emission layer provided between the first electrode and the second electrode is provided. The emission layer may include a polycyclic compound having N atoms and a B, two terphenyl groups bonded to a polycyclic ring, and a sterically bulky substituent such that the polycyclic compound has a sphere-like structure in three dimensions. The shape of the polycyclic compound may reduce aggregations, interactions, and / or the like between molecules of the polycyclic compound.

The present invention relates to an anthracene derivative compound having a characteristic structure in which an aryl group is introduced into a skeletal structure in which deuterium-substituted phenyl and anthracene are linked. In addition, the present invention relates to a high-efficiency, long-life organic light-emitting device of which the luminous efficiency and lifetime characteristics are significantly improved by employing a polycyclic compound having a characteristic structure as a dopant for a light-emitting layer while employing said compound as a host for the light-emitting layer. Furthermore, the present invention relates to a high-efficiency, long-life organic light-emitting device of which the luminous efficiency and lifetime characteristics are significantly improved by employing a polycyclic compound having a characteristic structure as a dopant for a light-emitting layer while forming a host of the light-emitting layer with a plurality of materials of one or more characteristic anthracene compounds in addition to said compound.

The invention relates to a synthesis method of a polycyclic compound and an intermediate, a long chain is synthesized firstly, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, a ring closing route and an intermediate are optimized, and the ring closing yield is improved.

The invention relates to a fused polycyclic compound, a preparation method thereof and application of the fused polycyclic compound in medicine. Specifically, the invention relates to a condensed polycyclic compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, the invention also relates to the use thereof as an Apelin receptor agonist, in particular as an Apelin receptor agonist and in the preparation of a medicament for the treatment and / or prevention of Apelin receptor mediated or dependent diseases or conditions. # imgabs0 #

A light emitting device according to an embodiment includes a first electrode and a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one among the plurality of organic layers includes a fused polycyclic compound represented by Formula 1 below, thereby showing improved emission efficiency.

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the polycyclic compound and application of the polycyclic compound as a therapeutic agent, especially application of the polycyclic compound as a BTK inhibitor or degradation agent and application of the polycyclic compound in preparation of drugs for treating and / or preventing BTK-mediated or dependent diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification.

The present invention provides a polycyclic compound, a pharmaceutical composition thereof, and a use thereof. The polycyclic compound of the present invention has a structure as shown in formula A, wherein the definitions of R1-R6, ring A-ring E, L, n, m, q, and t are as described herein. The compound of the present application is an RIPK1 inhibitor, which can be used for treating an RIPK1-related disease.

The invention relates to a light-emitting element, a fused polycyclic compound for the light-emitting element, and an electronic device including the light-emitting element. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode and including a fused polycyclic compound represented by Formula 1 as a first compound. Formula 1

The present invention relates to polycyclic compounds comprising electron-accepting pyrazine cores and one or more dendron-like donor groups. Such compounds have been shown to have properties advantageous for use in electroluminescent devices such as TADF. Thus, the invention also relates to uses of such compounds in electroluminescent devices, electroluminescent devices comprising such compounds, and methods of manufacturing such electroluminescent devices.

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, especially application of the compound as a CCR4 inhibitor and application of the compound in preparation of drugs for treating and / or preventing CCR4-mediated or dependent diseases or symptoms. # imgabs0 #

Disclosed are an organic electroluminescent material and a device thereof. The organic electroluminescent material is a polycyclic compound with a structure of formula 1, which can be used as a TADF material in an organic electroluminescent device. The polycyclic compound has a regulating effect on the emission color, can realize desired green light emission, has deeper HOMO and LUMO energy levels, has the potential to become an excellent light-emitting material, and has a very broad industrial application prospect. Also disclosed are an organic electroluminescent device comprising the compound and a compound composition comprising the compound.

A light emitting device of an embodiment includes a first electrode, a second electrode disposed on the first electrode, and at least one functional layer disposed between the first electrode and the second electrode. The at least one functional layer includes a polycyclic compound represented by Formula 1, thereby showing high emission efficiency properties and improved life characteristics.

A light emitting element includes a first electrode, a second electrode arranged on the first electrode, and an emission layer arranged between the first electrode and the second electrode and including a first compound represented by Formula 1.